Pfizer's Xyntha-administering syringe gets FDA approval
NEW YORK The Food and Drug Administration has approved a prefilled dual-chamber syringe made by Pfizer for treating hemophilia, Pfizer said.
The FDA approved the syringe for administering the drug Xyntha (antihemophilic factor [recombinant]) for hemophilia A. The drug is used to prevent and control bleeding episodes in patients.
“The approval of the pre-filled dual-chamber syringe is an important milestone for hemophilia patients due to its innovative, convenient reconstitution system that eliminates the transfer step,” Pfizer VP marketing for specialty biologics Emil Andrusko said.